Ajanta Pharma Limited 1.85 % Drug Manufacturers - Major

Trend Analysis

Loading...

Support and Resistance Levels Analysis
The current close value 1166.5 is between the support and resistance channel of 1148 and 1204. The stock has a Observe Signal , 1148 becomes a critical support to stop the fall and 1204 is a immediate resistance on the upside. Note that in case of a Observe Signal, the stocks tends to change trends. This happens mostly near the support and resistance levels.
Technical Indicators (3 Month duration)
Exponential Moving average 1154.3
MACD value 12.5
Price range 977.35 to 1187.55
Volume range 194882 to 442916
Support & Resistance 1148, 1204
Stock Performance
Six Months 2.5%
Five Months-4.8%
Four Months8.9%
Three Months15.5%
Two Months4.4%
One Month3.0%
Last Six Months

2.5%

Last Five Months

-4.8%

Last Four Months

8.9%

Last Three Months

15.5%

Last Two Months

4.4%

Last One Month

3.0%

Analysis
Volume
Today's Price Range
3 Month Price Range
About Ajanta Pharma Limited
Ajanta Pharma Limited is a pharmaceutical company engaged in development, research, manufacture and marketing of dosages in domestic and international markets. Ajanta operates with five manufacturing facilities, four in India and one in Mauritius that produce pharmaceutical products. It is engaged in commercializing generic products and combination products in the therapeutic areas of anti-malarial, cardiovascular, dermatology, male erectile dysfunction, musculoskeletal and ophthalmology. Its manufacturing capabilities include a range of dosage forms of allopathic drugs, including tablets, capsules, ointments, injections and dry powder. Its key products include the brand called Kamagra, for the treatment of Male Erectile Dysfunction (MED) and Artefan, for the treatment of malaria. The Companies subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., and Ajanta Pharma Philippines Inc.
See stocks similar to Ajanta Pharma Limited in Drug Manufacturers - Major

Ajanta Pharma Limited has Observe Signal. What is your opinion on it?

{ }